ClinicalTrials.gg
CompletedNCT01854645Updated Mar 28, 2017Results posted

Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)

A Phase 3 interventional study of GFF MDI and GP MDI in Chronic Obstructive Pulmonary Disease, sponsored by Pearl Therapeutics, Inc.. Completed at 140 sites in 3 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-03-28.

Sponsored by Pearl Therapeutics, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,103
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca — 14 open to participants now, 15 under way, 4 of them phase 3. Pulmonary Disease, Chronic Obstructive · AstraZeneca.

Enrollment
8th of 194
2,103 · median 137
Started
2013
with 13 others
Phase 3
76 of 284
4 open now
Registered
133rd of 284
by date

Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 8th largest by enrollment of the 194 interventional ones that give a count, is one of 14 that started in 2013, is one of 76 in phase 3, and was the 133rd registered.

Pulmonary Disease, Chronic Obstructive

5,526 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

14 of the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, or all of them as a file.
02

Study summary

The overall objective of this study is to assess the efficacy and safety of treatment with PT003 (GFF MDI), PT005 (FF MDI), PT001 (GP MDI), and open-label tiotropium bromide inhalation powder compared with each other and Placebo MDI over 24 weeks in subjects with moderate to very severe COPD.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male or female subjects at least 40 years of age and no older than 80 at Visit 1.
  • Subjects with an established clinical history of as defined by the American Thoracic Society (ATS)/European Respiratory Society (ERS)
  • Current or former smokers with a history of at least 10 pack-years of cigarette smoking.
  • Average f the -60 and the -30 min pre-dose assessments must be \< 80% predicted normal value calculated using National Health and Nutrition Examination Survey (NHANES) III reference equations.
  • Subjects willing and, in the opinion of the investigator, able to adjust current COPD therapy as required by the protocol

Key Exclusion Criteria:

  • Significant diseases other than COPD, i.e. disease or condition which, in the opinion of the investigator, may put the patient at risk because of participation in the study or may influence either the results of the study or the subject's ability to participate in the study
  • Current diagnosis of asthma or alpha-1 antitrypsin deficiency
  • Other active pulmonary disease such as active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, idiopathic interstitial pulmonary fibrosis, primary pulmonary hypertension, or uncontrolled sleep apnea
  • Hospitalized due to poorly controlled COPD within 3 months prior to screening or during the Screening Period
  • Poorly controlled COPD, defined as acute worsening of COPD that requires treatment with oral or antibiotics within 6 weeks prior to screening or during the Screening Period
  • Lower respiratory tract infections that required antibiotics within 6 weeks prior to screening or during the Screening Period
  • Unstable ischemic heart disease, left ventricular failure, or documented myocardial infarction within 12 months of enrollment.
  • Recent history of acute coronary syndrome, percutaneous coronary intervention, coronary artery bypass graft within the past three months
  • Congestive heart failure (CHF) (NYHA) Class III/IV)
  • abnormal 12-lead
  • Abnormal liver function tests defined as (AST), alanine transaminase (ALT), or total ≥ 1.5 times at Visit 1 and on repeat testing
  • Cancer not in complete remission for at least five years
  • History of to β2-agonists, glycopyrronium or other muscarinic anticholinergics, lactose/milk protein or any component of the MDI

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
2,103 participants (actual)

Study arms

  • Experimental
    GFF MDI

    Glycopyrronium Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) (PT003)

    Drug: GFF MDI

  • Experimental
    GP MDI

    Glycopyrronium (GP) MDI (PT001)

    Drug: GP MDI

  • Experimental
    FF MDI

    Formoterol Fumarate (FF) MDI (PT005)

    Drug: FF MDI

  • Active comparator
    Open-label tiotropium bromide inhalation powder

    Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®)

    Drug: Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®)

  • Placebo comparator
    Placebo

    Placebo MDI

    Drug: Placebo MDI

Interventions

  • DrugGFF MDI

    GFF MDI administered as two puffs Bis in Di.e. Twice Daily (BID)

  • DrugGP MDI

    GP MDI administered as two puffs BID

  • DrugFF MDI

    FF MDI administered as two puffs BID

  • DrugOpen-label tiotropium bromide inhalation powder (Spiriva® Handihaler®)

    Taken as 1 capsule daily containing 18 µg of open-label tiotropium via the Handihaler dry powder inhaler (DPI)

  • DrugPlacebo MDI

    Inhaled placebo administered as two puffs BID

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Morning Pre-dose Trough FEV1 at Week 24

    Change from baseline in morning pre-dose trough forced expiratory volume in 1 second (FEV1) at Week 24

    Time frame: Baseline and at Week 24

Secondary outcomes

  1. Change From Baseline in Morning Pre-dose Trough FEV1 Over 24 Weeks

    Change from baseline in morning pre-dose trough forced expiratory volume in 1 second (FEV1) over 24 weeks. FEV1 was assessed at multiple time points post-baseline,and a modelbased average of all visits starting from Week 2 through week 24 inclusive was calculated. The change values reported in the table represent the change between the baseline and the average FEV1 post-baseline.

    Time frame: Baseline and Weeks 2 to 24

  2. St. George's Respiratory Questionnaire (SGRQ) Score

    Change from baseline in the SGRQ total score. The SGRQ is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of GFF MDI, FF MDI and GP MDI on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (minimum, best possible health status) to 100 (maximum, worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline at a particular visit was calculated as the SGRQ total score at that visit minus Baseline. Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life.

    Time frame: Baseline and at Week 24

  3. Rescue Ventolin Hydrofluoroalkane (HFA) Use

    Change from baseline in average daily rescue Ventolin HFA use

    Time frame: Baseline and at Week 24

  4. Onset of Action as Assessed by FEV1

    Defined as the first time-point using the 5- and 15-minute post dose measurements where the difference in FEV1 from Placebo was statistically significant

    Time frame: Assessed for 5- and 15-minute post dose on Day 1

  5. Peak Change From Baseline in FEV1 Within 2 Hours Post-dose

    Peak change from baseline in forced expiratory volume in 1 second (FEV1) within 2 hours post-dose

    Time frame: Baseline and at Week 24

07

Results

Posted Mar 28, 2017

Participant flow

Conducted at 160 sites throughout the US, Australia, and New Zealand from June 2013 - February 2015. Study participation was a maximum of 32 weeks.

Participant flow — Overall Study
MilestoneGFF MDI (PT003)GP MDI (PT001)FF MDI (PT005)Spiriva® Handihaler® (Open-label)Placebo
Started527451452453220
Completed429345370391160
Not completed98106826260
Withdrew: Protocol-specified criteria1310857
Withdrew: Administrative reasons / missing00011
Withdrew: Protocol violation30541
Withdrew: Lost to follow-up107850
Withdrew: Physician decision15337
Withdrew: Withdrawal by subject3141302124
Withdrew: Lack of efficacy712939
Withdrew: Adverse event3331192011

Outcome measures

PrimaryChange From Baseline in Morning Pre-dose Trough FEV1 at Week 24

Change from baseline in morning pre-dose trough forced expiratory volume in 1 second (FEV1) at Week 24

Time frame:
Baseline and at Week 24
Reported as:
Least squares mean · Liters
Change From Baseline in Morning Pre-dose Trough FEV1 at Week 24
LitersGFF MDI (PT003)GP MDI (PT001)FF MDI (PT005)Spiriva® Handihaler® (Open-label)Placebo
Change From Baseline in Morning Pre-dose Trough FEV1 at Week 240.126 (0.107 to 0.145)0.066 (0.045 to 0.087)0.062 (0.041 to 0.082)0.105 (0.084 to 0.125)-0.024 (-0.055 to 0.007)
SecondaryChange From Baseline in Morning Pre-dose Trough FEV1 Over 24 Weeks

Change from baseline in morning pre-dose trough forced expiratory volume in 1 second (FEV1) over 24 weeks. FEV1 was assessed at multiple time points post-baseline,and a modelbased average of all visits starting from Week 2 through week 24 inclusive was calculated. The change values reported in the table represent the change between the baseline and the average FEV1 post-baseline.

Time frame:
Baseline and Weeks 2 to 24
Reported as:
Least squares mean · Liters
Change From Baseline in Morning Pre-dose Trough FEV1 Over 24 Weeks
LitersGFF MDI (PT003)GP MDI (PT001)FF MDI (PT005)Spiriva® Handihaler® (Open-label)Placebo
Change From Baseline in Morning Pre-dose Trough FEV1 Over 24 Weeks0.150 (0.136 to 0.164)0.091 (0.076 to 0.106)0.086 (0.071 to 0.101)0.122 (0.107 to 0.137)-0.007 (-0.029 to 0.015)
SecondarySt. George's Respiratory Questionnaire (SGRQ) Score

Change from baseline in the SGRQ total score. The SGRQ is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of GFF MDI, FF MDI and GP MDI on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (minimum, best possible health status) to 100 (maximum, worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline at a particular visit was calculated as the SGRQ total score at that visit minus Baseline. Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life.

Time frame:
Baseline and at Week 24
Reported as:
Least squares mean · Scores on a scale
St. George's Respiratory Questionnaire (SGRQ) Score
Scores on a scaleGFF MDI (PT003)GP MDI (PT001)FF MDI (PT005)Spiriva® Handihaler® (Open-label)Placebo
St. George's Respiratory Questionnaire (SGRQ) Score-3.1 (-4.0 to -2.2)-1.2 (-2.2 to -0.2)-2.4 (-3.4 to -1.4)-2.7 (-3.6 to -1.7)-0.8 (-2.2 to 0.7)
SecondaryRescue Ventolin Hydrofluoroalkane (HFA) Use

Change from baseline in average daily rescue Ventolin HFA use

Time frame:
Baseline and at Week 24
Reported as:
Least squares mean · Puffs / Day
Rescue Ventolin Hydrofluoroalkane (HFA) Use
Puffs / DayGFF MDI (PT003)GP MDI (PT001)FF MDI (PT005)Spiriva® Handihaler® (Open-label)Placebo
Rescue Ventolin Hydrofluoroalkane (HFA) Use-0.8 (-1.0 to -0.6)-0.5 (-0.7 to -0.3)-0.8 (-1.0 to -0.6)-0.4 (-0.6 to -0.2)0.3 (0.0 to 0.6)
SecondaryOnset of Action as Assessed by FEV1

Defined as the first time-point using the 5- and 15-minute post dose measurements where the difference in FEV1 from Placebo was statistically significant

Time frame:
Assessed for 5- and 15-minute post dose on Day 1
Reported as:
Least squares mean · Liters
Onset of Action as Assessed by FEV1
LitersGFF MDI (PT003)GP MDI (PT001)FF MDI (PT005)Spiriva® Handihaler® (Open-label)Placebo
5 min post dose0.185 (0.175 to 0.195)0.042 (0.031 to 0.053)0.182 (0.171 to 0.193)0.048 (0.037 to 0.059)-0.002 (-0.017 to 0.014)
15 min post dose0.226 (0.216 to 0.237)0.101 (0.090 to 0.113)0.212 (0.201 to 0.224)0.117 (0.105 to 0.129)0.022 (0.005 to 0.038)
Statistical analysis
  • GFF MDI (PT003) vs Placebo · ANCOVA · p = <0.0001
  • GFF MDI (PT003) vs Placebo · ANCOVA · p = <0.0001
  • GP MDI (PT001) vs Placebo · ANCOVA · p = <0.0001
  • GP MDI (PT001) vs Placebo · ANCOVA · p = <0.0001
  • FF MDI (PT005) vs Placebo · ANCOVA · p = <0.0001
  • FF MDI (PT005) vs Placebo · ANCOVA · p = <0.0001
SecondaryPeak Change From Baseline in FEV1 Within 2 Hours Post-dose

Peak change from baseline in forced expiratory volume in 1 second (FEV1) within 2 hours post-dose

Time frame:
Baseline and at Week 24
Reported as:
Least squares mean · Liters
Peak Change From Baseline in FEV1 Within 2 Hours Post-dose
LitersGFF MDI (PT003)GP MDI (PT001)FF MDI (PT005)Spiriva® Handihaler® (Open-label)Placebo
Peak Change From Baseline in FEV1 Within 2 Hours Post-dose0.356 (0.335 to 0.377)0.223 (0.200 to 0.246)0.263 (0.240 to 0.285)0.259 (0.237 to 0.281)0.065 (0.031 to 0.098)

Adverse events

Collected over SAEs and AEs were collected throughout study participation and for two weeks after study completion.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GFF MDI (PT003)—44/526 (8.4%)73/526 (13.9%)
GP MDI (PT001)—36/451 (8%)59/451 (13.1%)
FF MDI (PT005)—29/452 (6.4%)57/452 (12.6%)
Spiriva® Handihaler® (Open-label)—36/451 (8%)58/451 (12.9%)
Placebo—16/220 (7.3%)47/220 (21.4%)
Most frequent serious events
Showing 10 of 101
Most frequent serious events
EventGFF MDI (PT003)GP MDI (PT001)FF MDI (PT005)Spiriva® Handihaler® (Open-label)Placebo
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders15/52617/4518/4528/4517/220
PneumoniaInfections and infestations8/5267/4510/4521/4511/220
Chest painGeneral disorders1/5262/4511/4520/4512/220
Squamous cell carcinoma of lungNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/5260/4510/4523/4510/220
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/5260/4510/4520/4511/220
EpistatxisRespiratory, thoracic and mediastinal disorders0/5260/4510/4520/4511/220
CellulitisInfections and infestations1/5260/4510/4522/4511/220
PyelonephritisInfections and infestations0/5260/4510/4520/4511/220
Coronary artery diseaseCardiac disorders1/5261/4510/4521/4511/220
Acute myocardial infarctionCardiac disorders1/5261/4510/4520/4511/220
Most frequent other events
Most frequent other events
EventGFF MDI (PT003)GP MDI (PT001)FF MDI (PT005)Spiriva® Handihaler® (Open-label)Placebo
NasopharyngitisInfections and infestations43/52623/45128/45226/45118/220
Upper respiratory tract infectionInfections and infestations17/52620/45114/45217/45116/220
DyspnoeaRespiratory, thoracic and mediastinal disorders13/52616/45115/45215/45113/220

Baseline characteristics

7 subjects were excluded from analysis.

Age, Continuous
Age, Continuous(Years)GFF MDI (PT003)GP MDI (PT001)FF MDI (PT005)Spiriva® Handihaler® (Open-label)PlaceboTotal
Mean62.6 ± 8.462.9 ± 8.463.0 ± 8.363.0 ± 8.662.5 ± 8.362.8 ± 8.4
Sex: Female, Male
Sex: Female, Male(Participants)GFF MDI (PT003)GP MDI (PT001)FF MDI (PT005)Spiriva® Handihaler® (Open-label)PlaceboTotal
Female23619620318297914
Male2902552462691221182
08

Study locations

140 sites
  • Pearl Investigative Site
    Andalusia, Alabama, United States
  • Pearl Investigative Site
    Anniston, Alabama, United States
  • Pearl Investigative Site
    Athens, Alabama, United States
  • Pearl Investigative Site
    Birmingham, Alabama, United States
  • Pearl Investigative Site
    Mesa, Arizona, United States
  • Pearl Investigative Site
    Phoenix, Arizona, United States
  • Pearl Investigative Site
    Scottsdale, Arizona, United States
  • Pearl Investigative Site
    Tucson, Arizona, United States
  • Pearl Investigative Site
    Anaheim, California, United States
  • Pearl Investigative Site
    Carlsbad, California, United States
  • Pearl Investigative Site
    Lakewood, California, United States
  • Pearl Investigative Site
    Los Angeles, California, United States
  • Pearl Investigative Site
    Pasadena, California, United States
  • Pearl Investigative Site
    Pasedena, California, United States
  • Pearl Investigative Site
    Poway, California, United States
  • Pearl Investigative Site
    Sacramento, California, United States
  • Pearl Investigative Site
    San Diego, California, United States
  • Pearl Investigative Site
    Tustin, California, United States
  • Pearl Investigative Site
    Vista, California, United States
  • Pearl Investigative Site
    Colorado Springs, Colorado, United States
  • Pearl Investigative Site
    Denver, Colorado, United States
  • Pearl Investigative Site
    Fort Collins, Colorado, United States
  • Pearl Investigative Site
    Wheat Ridge, Colorado, United States
  • Pearl Investigative Site
    Danbury, Connecticut, United States
  • Pearl Investigative Site
    Waterbury, Connecticut, United States
  • Pearl Investigative Site
    Brandon, Florida, United States
  • Pearl Investigative Site
    Clearwater, Florida, United States
  • Pearl Investigative Site
    Lehigh Acres, Florida, United States
  • Pearl Investigative Site
    Miami, Florida, United States
  • Pearl Investigative Site
    Ormond Beach, Florida, United States
  • Pearl Investigative Site
    Panama City, Florida, United States
  • Pearl Investigative Site
    Pensacola, Florida, United States
  • Pearl Investigative Site
    St. Petersburg, Florida, United States
  • Pearl Investigative Site
    Tampa, Florida, United States
  • Pearl Investigative Site
    Winter Park, Florida, United States
  • Pearl Investigative Site
    Atlanta, Georgia, United States
  • Pearl Investigative Site
    Austell, Georgia, United States
  • Pearl Investigative Site
    Columbus, Georgia, United States
  • Pearl Investigative Site
    Duluth, Georgia, United States
  • Pearl Investigative Site
    Gainesville, Georgia, United States
  • Pearl Investigative Site
    Coeur d'Alene, Idaho, United States
  • Pearl Investigative Site
    Champaign, Illinois, United States
  • Pearl Investigative Site
    Evanston, Illinois, United States
  • Pearl Investigative Site
    Peoria, Illinois, United States
  • Pearl Investigative Site
    River Forest, Illinois, United States
  • Pearl Investigative Site
    Anderson, Indiana, United States
  • Pearl Investigative Site
    Avon, Indiana, United States
  • Pearl Investigative Site
    Elwood, Indiana, United States
  • Pearl Investigative Site
    Evansville, Indiana, United States
  • Pearl Investigative Site
    Iowa City, Iowa, United States
  • Pearl Investigative Site
    Topeka, Kansas, United States
  • Pearl Investigative Site
    Louisville, Kentucky, United States
  • Pearl Investigative Site
    Lafayette, Louisiana, United States
  • Pearl Investigative Site
    Sunset, Louisiana, United States
  • Pearl Investigative Site
    Baltimore, Maryland, United States
  • Pearl Investigative Site
    Hollywood, Maryland, United States
  • Pearl Investigative Site
    Livonia, Michigan, United States
  • Pearl Investigative Site
    Southfield, Michigan, United States
  • Pearl Investigative Site
    Edina, Minnesota, United States
  • Pearl Investigative Site
    Fridley, Minnesota, United States
  • Pearl Investigative Site
    Minneapolis, Minnesota, United States
  • Pearl Investigative Site
    Woodbury, Minnesota, United States
  • Pearl Investigative Site
    Springfield, Missouri, United States
  • Pearl Investigative Site
    St Louis, Missouri, United States
  • Pearl Investigative Site
    St. Charles, Missouri, United States
  • Pearl Investigative Site
    Missoula, Montana, United States
  • Pearl Investigative Site
    Bellevue, Nebraska, United States
  • Pearl Investigative Site
    Omaha, Nebraska, United States
  • Pearl Investigative Site
    Las Vegas, Nevada, United States
  • Pearl Investigative Site
    Ocean, New Jersey, United States
  • Pearl Investigative Site
    Albuquerque, New Mexico, United States
  • Pearl Investigative Site
    Corning, New York, United States
  • Pearl Investigative Site
    Burlington, North Carolina, United States
  • Pearl Investigative Site
    Charlotte, North Carolina, United States
  • Pearl Investigative Site
    Greensboro, North Carolina, United States
  • Pearl Investigative Site
    Huntersville, North Carolina, United States
  • Pearl Investigative Site
    Raleigh, North Carolina, United States
  • Pearl Investigative Site
    Wilmington, North Carolina, United States
  • Pearl Investigative Site
    Winston-Salem, North Carolina, United States
  • Pearl Investigative Site
    Cincinnati, Ohio, United States
  • Pearl Investigative Site
    Columbus, Ohio, United States
  • Pearl Investigative Site
    Dayton, Ohio, United States
  • Pearl Investigative Site
    Dublin, Ohio, United States
  • Pearl Investigative Site
    Oregon, Ohio, United States
  • Pearl Investigative Site
    Bend, Oregon, United States
  • Pearl Investigative Site
    Medford, Oregon, United States
  • Pearl Investigative Site
    Portland, Oregon, United States
  • Pearl Investigative Site
    Monroeville, Pennsylvania, United States
  • Pearl Investigative Site
    Philadelphia, Pennsylvania, United States
  • Pearl Investigative Site
    Charleston, South Carolina, United States
  • Pearl Investigative Site
    Easley, South Carolina, United States
  • Pearl Investigative Site
    Gaffney, South Carolina, United States
  • Pearl Investigative Site
    Greenville, South Carolina, United States
  • Pearl Investigative Site
    Mt. Pleasant, South Carolina, United States
  • Pearl Investigative Site
    Murrells Inlet, South Carolina, United States
  • Pearl Investigative Site
    Myrtle Beach, South Carolina, United States
  • Pearl Investigative Site
    Rock Hill, South Carolina, United States
  • Pearl Investigative Site
    Spartanburg, South Carolina, United States
  • Pearl Investigative Site
    Union, South Carolina, United States
  • Pearl Investigative Site
    Rapid City, South Dakota, United States

Showing the first 100 of 140 sites across 3 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Singh D, Hurst JR, Martinez FJ, Rabe KF, Bafadhel M, Jenkins M, Salazar D, Dorinsky P, Darken P. Predictive modeling of COPD exacerbation rates using baseline risk factors. Ther Adv Respir Dis. 2022 Jan-Dec;16:17534666221107314. doi: 10.1177/17534666221107314. PubMed 35815359 ↗
  • Martinez FJ, Lipworth BJ, Rabe KF, Collier DJ, Ferguson GT, Sethi S, Feldman GJ, O'Brien G, Jenkins M, Reisner C. Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies. Respir Res. 2020 May 25;21(1):128. doi: 10.1186/s12931-020-01388-y. PubMed 32450869 ↗
  • Martinez FJ, Rabe KF, Lipworth BJ, Arora S, Jenkins M, Martin UJ, Reisner C. Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies. Int J Chron Obstruct Pulmon Dis. 2020 Jan 9;15:99-106. doi: 10.2147/COPD.S229794. eCollection 2020. PubMed 32021148 ↗
  • Martinez FJ, Fabbri LM, Ferguson GT, Orevillo C, Darken P, Martin UJ, Reisner C. Baseline Symptom Score Impact on Benefits of Glycopyrrolate/Formoterol Metered Dose Inhaler in COPD. Chest. 2017 Dec;152(6):1169-1178. doi: 10.1016/j.chest.2017.07.007. Epub 2017 Jul 16. PubMed 28720336 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2013, a primary completion of Feb 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2017, 2 years 1 month after primary completion. A results delay was requested in Jul 2015.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2013
First posted
May 15, 2013
Start
May 2013
Primary completionActual
Feb 2015
CompletionActual
Feb 2015
Results delay requested
Jul 7, 2015
Results first posted
Mar 28, 2017
Last update
Mar 28, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01854645
Responsible party
Sponsor
First posted
May 15, 2013
Start date
May 2013
Primary completion
Feb 2015
Completion
Feb 2015
Results posted
Mar 28, 2017
Last update
Mar 28, 2017

Study contacts

Colin Reisner, MD
study director · Pearl Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion